Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

NCT00095654 is registered in ClinicalTrials.gov with Gerstein, Hertzel, MD as lead sponsor.

NCT NCT00095654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Lead sponsor
Gerstein, Hertzel, MD
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2001
Completion date
October 31, 2006
Enrollment
5,000
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, glucose metabolism disorders, impaired glucose tolerance